Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be
treated with radiotherapy/chemotherapy followed by dendritic cell vaccine. Chemotherapy will
be administered after three vaccinations for one year or until progression of disease.